E16.2

Hypoglycemia, unspecified

Hypoglycemia, unspecified (E16.2), is a clinical syndrome characterized by a reduction in blood glucose to a level that may lead to symptoms of neuroglycopenia and autonomic nervous system activation. In adults, this is generally defined as a blood glucose concentration below 70 mg/dL (3.9 mmol/L). The condition is traditionally confirmed via Whipple’s Triad: the presence of symptoms consistent with hypoglycemia, a documented low plasma glucose concentration, and the prompt resolution of symptoms following the administration of glucose. While most frequently encountered as a complication of pharmacological management in patients with Diabetes Mellitus (often requiring more specific codes like E10.649 or E11.649), E16.2 serves as the primary diagnostic code when the underlying etiology is not yet determined or specified. Physiologically, the body attempts to compensate for low glucose through a counter-regulatory surge involving glucagon and epinephrine, which stimulate glycogenolysis and gluconeogenesis, and cortisol and growth hormone, which limit peripheral glucose utilization.

Clinical Symptoms

  • Diaphoresis (excessive sweating)
  • Tachycardia and palpitations
  • Tremors and shakiness
  • Intense hunger (polyphagia)
  • Anxiety and nervousness
  • Confusion and altered mental status
  • Dizziness or lightheadedness
  • Blurred or double vision
  • Fatigue and generalized weakness
  • Irritability or uncharacteristic behavioral changes
  • Slurred speech
  • Seizures
  • Loss of consciousness or coma
  • Paresthesia (numbness/tingling), often circumoral

Common Causes

  • Excessive exogenous insulin administration
  • Oral hypoglycemic agents (particularly sulfonylureas and meglitinides)
  • Excessive alcohol consumption (inhibiting hepatic gluconeogenesis)
  • Severe hepatic failure or cirrhosis
  • End-stage renal disease (impaired insulin clearance)
  • Insulinoma (insulin-secreting pancreatic tumor)
  • Non-islet cell tumor hypoglycemia (NICTH)
  • Post-prandial reactive states (e.g., following gastric bypass surgery)
  • Adrenal insufficiency (Addison's disease)
  • Pituitary insufficiency (Growth hormone deficiency)
  • Sepsis and overwhelming systemic infection
  • Prolonged starvation or severe malnutrition

Documentation & Coding Tips

Distinguish between fasting and reactive states to avoid unspecified coding when more detail is available.

Example: Patient presents with symptoms of shakiness and confusion occurring 2 hours after high-carbohydrate meals. Capillary blood glucose documented at 54 mg/dL. This reactive pattern suggests postprandial hypoglycemia, though diagnostic workup for insulinoma versus late dumping syndrome is ongoing. Plan: Initiate small, frequent meals and monitor with CGM.

Billing Focus: Documentation of timing relative to meals helps differentiate between E16.1 (Other hypoglycemia) and E16.2 (Unspecified).

Explicitly document the presence or absence of Whipples Triad to confirm clinical diagnosis.

Example: Patient exhibited symptomatic hypoglycemia (tachycardia, diaphoresis) with a laboratory-confirmed plasma glucose of 48 mg/dL. Immediate resolution of all neuroglycopenic symptoms followed administration of 25g IV Dextrose 50 percent. This confirms Whipples Triad for a hypoglycemic event of unknown etiology.

Billing Focus: Inclusion of laboratory values and symptom resolution provides clinical validation for the diagnosis code in the event of a payer audit.

Document if the hypoglycemia is iatrogenic or drug-induced even in patients without diabetes.

Example: 72-year-old female without history of diabetes presented with lethargy. Found to have blood glucose of 52 mg/dL. Review of medications reveals recent initiation of Quinine for leg cramps, which is the suspected causative agent for this drug-induced hypoglycemic episode. Quinine discontinued.

Billing Focus: If a specific drug is identified, code E16.0 (Drug-induced hypoglycemia without diabetes) along with the appropriate T-code for the adverse effect (e.g., T43.595A).

Specify the severity of neuroglycopenic symptoms to justify the level of care.

Example: Patient presented with altered mental status and combativeness. Point-of-care testing showed a glucose level of 39 mg/dL. Condition was refractory to oral glucose, requiring glucagon IM and subsequent IV D5W infusion. Vital signs remained stable, but neuro-checks were performed every 15 minutes until baseline mentation returned.

Billing Focus: Severe symptoms like combativeness or seizure (R56.9) should be documented as secondary diagnoses to reflect the complexity of the encounter.

Clearly link hypoglycemia to underlying organ failure if applicable.

Example: Hypoglycemic event (glucose 55 mg/dL) noted in the setting of end-stage renal disease (ESRD) and congestive heart failure (CHF). Reduced clearance of endogenous insulin and impaired gluconeogenesis due to hepatic congestion are likely contributing factors. Patient does not have a diagnosis of diabetes mellitus.

Billing Focus: Linkage statements like due to or in the setting of help support the use of codes for the primary causative conditions.

Relevant CPT Codes

Related Diagnoses

Hierarchy